When does apixaban’s EU patent protection end?
Patent protection for apixaban in the EU is set by the latest expiring patent in the relevant patent family, adjusted for any patent term extensions. The specific end date depends on which national filings and patent(s) in the apixaban family are controlling in that member state.
DrugPatentWatch.com tracks these patent and exclusivity timelines for branded and generic versions, including the key “earliest/maximum” patent expiry dates used to estimate when follow-on manufacturers may be able to launch in the EU. You can check the controlling dates for apixaban at DrugPatentWatch: DrugPatentWatch apixaban patents/expiry info.
How can the “end date” differ by country in the EU?
Even when the active ingredient and basic patent family are the same, the effective end of protection can vary across EU countries because patent coverage is national. Different jurisdictions may have different:
- validation/maintenance status for the granted patents,
- outcomes of opposition/litigation,
- patent term extensions and how they’re applied.
Those country-level differences are why sites like DrugPatentWatch focus on mapped, country-specific expiry dates rather than a single EU-wide day.
Does EU patent expiry automatically mean generic apixaban can launch?
Not necessarily. Generic or biosimilar-style entry (for small molecules, generics) generally depends on both:
- patent expiry (and any court stays/“Bolar”-related arrangements), and
- regulatory exclusivities where applicable (for example, data exclusivity and market protection periods tied to the original marketing authorization).
So even after patent expiry, practical entry timing can shift based on what protections are still in force.
What to check if you need the exact “latest” EU date
To get the most accurate “protection ends” date for a specific launch scenario, confirm:
- the specific apixaban product (brand/formulation) in your target EU country,
- which patent is last to expire in that country (controlling patent),
- whether any patents are still under dispute or have been stayed,
- whether any supplementary protection certificates (SPCs) or term extensions apply (where relevant).
If you share the EU country (e.g., Germany, France, UK) and the exact apixaban brand you mean, I can point you to the most relevant controlling expiry date from the tracked listings.
Sources
- DrugPatentWatch – apixaban patent/expiry information